

FOI_1526_2023-24 – FOI Request concerning Encorafenib (Braftovi) + Binimetnib (Mektovi) Treatments

Please be advised, with regards to the questions below, Solent NHS Trust does not provide this treatment and therefore are unable to answer these questions.

- 1. In the past 6 months, how many patients were treated with a combination of both Encorafenib (Braftovi) + Binimetnib (Mektovi) for the following diseases:
 - a) Metastatic Melanoma
 - b) Colorectal Cancer
 - c) Any other indications
- 2. In the past 6 months, how many patients were treated with a combination of Dabrafenib + Trametinib for the following diseases:
 - a) Metastatic Melanoma
 - b) Adjuvant Melanoma
 - c) BRAF mutated Lung Cancer

